Metformin hydrochloride; saxagliptin hydrochloride - Generic Drug Details

What are the generic drug sources for metformin hydrochloride; saxagliptin hydrochloride and what is the scope of patent protection?

Metformin hydrochloride; saxagliptin hydrochloride is the generic ingredient in two branded drugs marketed by Astrazeneca Ab, Dr Reddys Labs Sa, Mylan, and Sun Pharm, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.

Three suppliers are listed for this compound.

Summary for metformin hydrochloride; saxagliptin hydrochloride

US Patents:	0
Tradenames:	2
Applicants:	4
NDAs:	4
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	3
Clinical Trials:	61
Patent Applications:	360
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for metformin hydrochloride; saxagliptin hydrochloride
DailyMed Link:	metformin hydrochloride; saxagliptin hydrochloride at DailyMed

Recent Clinical Trials for metformin hydrochloride; saxagliptin hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair	PHASE2
UnitedHealthcare	PHASE2
Sabyasachi Sen	Phase 4

See all metformin hydrochloride; saxagliptin hydrochloride clinical trials

Pharmacology for metformin hydrochloride; saxagliptin hydrochloride

Drug Class	Biguanide Dipeptidyl Peptidase 4 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for metformin hydrochloride; saxagliptin hydrochloride

A10BA	Biguanides
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

A10BH	Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KOMBIGLYZE XR	Extended-release Tablets	metformin hydrochloride; saxagliptin hydrochloride	5 mg/500 mg 2.5 mg/1000 mg 5 mg/1000 mg	200678	3	2013-07-31

US Patents and Regulatory Information for metformin hydrochloride; saxagliptin hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan	SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205981-003	Jul 31, 2023	AB	RX	No	No
Astrazeneca Ab	KOMBIGLYZE XR	metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200678-003	Nov 5, 2010		DISCN	Yes	No
Mylan	SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205981-001	Jul 31, 2023	AB	RX	No	No
Sun Pharm	SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	206081-002	Jul 31, 2023		DISCN	No	No
Dr Reddys Labs Sa	SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE	metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	207678-001	Aug 9, 2023	AB	RX	No	No

Expired US Patents for metformin hydrochloride; saxagliptin hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca Ab	KOMBIGLYZE XR	metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200678-001	Nov 5, 2010
Astrazeneca Ab	KOMBIGLYZE XR	metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200678-003	Nov 5, 2010
Astrazeneca Ab	KOMBIGLYZE XR	metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200678-001	Nov 5, 2010
Astrazeneca Ab	KOMBIGLYZE XR	metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200678-002	Nov 5, 2010
Astrazeneca Ab	KOMBIGLYZE XR	metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200678-001	Nov 5, 2010

Market Dynamics and Financial Trajectory for Metformin Hydrochloride and Saxagliptin Hydrochloride

Last updated: February 13, 2026

Overview

Metformin Hydrochloride (Metformin) and Saxagliptin Hydrochloride (Saxagliptin) are key drugs in type 2 diabetes management. Their market positions are influenced by demographic trends, regulatory environments, patent statuses, and competitive landscapes.

---

Market Size and Growth Trends

Global Market Value (2022)

• Metformin: Estimated at $1.2 billion, representing approximately 70% of the oral antidiabetic market.
• Saxagliptin: Estimated at $600 million, accounting for 22% of the class segment of DPP-4 inhibitors.
• Total oral antidiabetic drugs market: ~$1.7 billion, projected to grow at a compound annual growth rate (CAGR) of 5.2% through 2027.

Historical Growth

• Metformin's market has seen slow but steady growth since its introduction in the 1950s, driven by its efficacy, safety, and low cost.
• Saxagliptin was approved in 2013 by the FDA; its market uptake reflects the growing preference for DPP-4 inhibitors following the decline of prior therapies like sulfonylureas in some segments.

---

Demand Drivers

• Rising Prevalence of Type 2 Diabetes: According to the International Diabetes Federation, global cases exceed 440 million, predicted to reach 700 million by 2045.
• Aging Populations: Older demographics increase demand for chronic disease drugs.
• Cost-Effectiveness of Metformin: Particularly in developing nations, where affordability remains critical.
• Introduction of Combination Therapies: Fixed-dose combinations improve adherence, integrating Metformin and Saxagliptin.

---

Regulatory and Patent Landscapes

Patents

• Metformin: Patents expired globally by the late 2000s, leading to widespread generic manufacturing.
• Saxagliptin: U.S. patent expired in 2022; generic versions are expected to enter the market, intensifying competition.

Regulatory Environment

• Approval extensions and generic authorizations impact pricing and market share.
• Emerging markets tend to have less restrictive patent enforcement, promoting generic penetration earlier.

---

Competitive Landscape

Drug Class	Main Competitors	Market Share (2022)	Key Differentiators
Biguanides	Metformin, Glucophage (brand)	70% of oral market	Cost, extensive clinical data
DPP-4 Inhibitors	Saxagliptin, Sitagliptin, Linagliptin	22% of DPP-4 segment	Efficacy, safety profile

• Generics: The transition to generics for both drugs is expected to lower prices and expand access.
• Innovation: Limited recent innovation in these classes; most new entries are generics or biosimilars.

---

Pricing & Revenue Projections

Current Pricing (U.S.)

• Brand-name Metformin: Approximately $4-8 per month.
• Generic Metformin: Under $1 per month.
• Saxagliptin: Brand-name ~$300 per year.
• Generic Saxagliptin: Expected prices around $50-100 per year upon market entry.

Projected Revenue Trends (2023-2027)

• Metformin: Revenue growth stabilizes; price erosion consistent due to generics.
• Saxagliptin: Growth potential exists if brand exclusivity continues; then, rapid decline expected post-generic entry.

---

Impacts of Biosimilars and Generics

The expiration of patents influences price competition, with generics reducing retail prices by up to 80-90%. Historical data show that post-patent expiration, market share shifts rapidly to generics, with a 50% or higher adoption rate within two years.

Market Risks and Challenges

• Pricing Pressure: Intensified by generic entries.
• Regulatory Delay: Potential delays in approval for new formulations or biosimilars.
• Market Saturation: High baseline penetration limits explosive growth.

---

Summary

While Metformin maintains dominance due to its proven efficacy and affordability, Saxagliptin's commercial prospects will depend on patent protections, generic competition, and positioning within combination therapies. Both drugs face accelerated price declines post-patent expiry but remain essential components of diabetes management protocols.

---

Key Takeaways

• The global oral antidiabetic market is growing at over 5% CAGR, driven by increasing diabetes prevalence.
• Metformin's market is mature, with widespread generics reducing revenue opportunities but supporting high-volume sales.
• Saxagliptin's market share is stable but vulnerable to generic competition post-2022.
• Price erosion is a significant factor post-patent expiry; health systems favor low-cost options.
• Innovation within these classes is limited; future growth depends on new combination formulations and alternative mechanisms.

---

FAQs

1. Will the market for Metformin decline once generics dominate?
   Yes; volume sales remain steady, but revenue decreases as prices fall.

2. What is the impact of patent expiration on Saxagliptin?
   Patent expiration in 2022 will allow generics, leading to price reductions and potential market share loss.

3. Are there new drugs replacing Metformin or Saxagliptin?
   No. They remain first-line therapies; newer drugs target different mechanisms or improved safety profiles.

4. How does the global trend in diabetes affect these drugs?
   Rising prevalence supports ongoing demand, but cost considerations heavily influence market share.

5. What is the outlook for combination therapies involving these drugs?
   Growing; fixed-dose combinations enhance adherence and capture market share from monotherapies.

---

References

[1] International Diabetes Federation. IDF Diabetes Atlas, 2022.
[2] Evaluate Pharma. 2023 Global Market Data Report.
[3] FDA. Saxagliptin (Onglyza) Approval and Patent Status Updates.
[4] IQVIA. World Review of Diabetes Market Trends, 2023.